Narrative review / 2021
A review highlights the therapeutic potential of NAD+ precursors like NR, NMN, and NRH for aging, metabolic, and neurodegenerative conditions.
This review summarizes preclinical and clinical evidence on the biological activity, safety, and potential side effects of NAD+ precursors, focusing on nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and dihydronicotinamide riboside (NRH). Emerging data indicate an age-dependent reduction in cellular NAD+. In preclinical models, replenishing NAD+ extends healthspan or lifespan and mitigates conditions such as premature aging and neurodegenerative diseases.
- Study type
- Narrative review
- Who was studied
- Preclinical and clinical studies
- What was measured
- Biological activity, safety, and possible side effects of NAD+ precursors
THE PAPER
Preclinical and clinical evidence of NAD+ precursors in health, disease, and ageing.
Reiten OK, Wilvang MA, Mitchell SJ, Hu Z, Fang EF. Mech Ageing Dev, 2021.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.